Logo

Melanoma

News and reporting on melanoma.

DermTech Q1 Revenues up 62 Percent

The firm processed approximately 9,400 billable samples in Q1, a 62 percent increase compared to approximately 5,800 samples in Q1 of 2020.

Castle Biosciences Q1 Revenues Up 31 Percent

The company said it delivered 11 percent fewer DecisionDx-Melanoma test results year over year, but that the total number of all tests delivered rose 4 percent.

Castle Biosciences Q4 Revenues Down 2 Percent

The skin cancer diagnostics company said it delivered 5 percent fewer DecisionDx-Melanoma test results in Q4 2020 than in the previous year's fourth quarter.

Circulating Tumor DNA Provides Prognostic Clues in Advanced BRAF-Mutated Melanoma Cases

Using the BRAF-V600 tumor mutation as a marker, investigators identified pre-treatment and on-treatment ties between ctDNA and patient outcomes.

DermTech Using $144M Financing to Spur Marketing, Telemedicine Efforts For Molecular Melanoma Assay
Premium

The firm expects to increase commercial coverage for its pigmented lesion assay for melanoma while widening its pipeline to diagnose other varieties of skin cancer.

Jan 22, 2021

Oppenheimer Initiates Coverage of DermTech With Outperform Rating

Jan 19, 2021

OncoHost Raises $8 Million in Series B Funding Round

Dec 23, 2020

Personalis Sees New Neoantigen Platform Driving Improved Immunotherapy Prediction
Premium

Dec 14, 2020

Craig-Hallum Initiates Coverage of DermTech With Buy Rating

Dec 10, 2020

Apis Assay Technologies, Moffitt Cancer Center to Evaluate RNA Biomarkers for Cancer Progression

Dec 3, 2020

Local Coverage Determinations Roundup: Castle Bio

Nov 18, 2020

IsoPlexis Targets New Market Segments With Cheaper, More Flexible Single-Cell Proteomic Systems
Premium

Nov 16, 2020

Somatic Mutations in Lung Cancer Patients With HLA Supertype B44 Influence Immunotherapy Response

Nov 9, 2020

Castle Biosciences Q3 Revenues Up 3 Percent

Nov 6, 2020

Medicare Administrative Contractor CGS Aligns Coverage for Melanoma Risk Stratification Tests

Oct 23, 2020

Melanoma Treatment Stage Affects Ability of Liquid Biopsy to Predict Immunotherapy Benefit
Premium

Oct 22, 2020

Local Coverage Determinations Roundup: CareDx, Castle Bio, Decipher Biosciences

Oct 8, 2020

Castle Bio Receives Expanded Medicare Coverage for Melanoma Test

Oct 7, 2020

Post-mortem Melanocyte Mutations Provide Melanoma Clues

Sep 23, 2020

Pale Melanoma Susceptibility Linked to Albinism-Related Genes

Sep 10, 2020

Cowen Initiates Coverage of DermTech With Outperform Rating

Aug 19, 2020

Antegenes Receives CE Marks for Cancer, Melanoma Polygenic Risk Score Tests

Aug 10, 2020

Castle Biosciences Q2 Revenues Up 18 Percent

Jul 30, 2020

Heritable Gene Expression in Single Cells Leads to Subpopulations With Marked Behaviors

Jul 27, 2020

Oncology Informatics Firm Vidence Emerges to Supply Real-World Clinical, Genomic Data to Researchers
Premium

Breaking News
The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.